Construction of human eukaryotic expression plasmid vascular endothelial growth factor 165 and its expression in transfected vascular smooth muscles

BACKGROUND: The highly specific vascular endothelialgrowth factor (VEGF) induces the growth of vascular en-dothelial cell. This study was to construct the eukaryoticexpression plasmid of vascular endothelial growth factorl65(VEGF165) and observe its expression in vascular smoothmuscles (VSMCs).METHODS: The primers were designed and synthesizedaccording to the gene sequences of human VEGF165. TheVEGF165 gene was obtained from umbilic artery tissue bythe method of RT-PCR, then it was cloned to eukaryoticexpression plasmid pBudCE4.1 by recombination strategy.The eukaryotic expression plasmid named pBudCE4.1/VEGF165 was identified by restriction enzyme digestion,and was sequenced. The pBudCE4.1/VEGF165 was trans-fected into VSMCs by using lipofection. The VEGF165 ex-pression of mRNA and protein was detected by RT-PCRand Western blot respectively.RESULTS: VEGF165 was shown about 576bp by RT-PCR.Sequencing revealed the amplified VEGF165 gene was iden-tical with that in the GeneBank. Restrictive enzyme (HindBam HI) digestion analysis showed that recombinantexpression plasmid pBudCE4. l/tVEGF165 had been con-structed successfully. The expression of VEGF165 at mRNAand protein levels in the transformed VSMCs had beendemonstrated by RT-PCR and Western blot.CONCLUSIONS: The recombinant eukaryotic expressionplasmid pBudCE4.1/VEGF165 has been successfully con-structed and expressed in transformed VSMCs. The presentstudy has laid a foundation for VEGF165 gene therapy ofvascular stenosis in the transplant organ.

Construction of human VEGF165 gene eukaryotic expression plasmid and its effect on proliferation of vascular endothelial cells

After organ transplantation, rapid repair of injured vascular endothelial cell (VEC) is a key to prevent graft chronic dysfunction besides control of immunological rejection. Many studies have confirmed that vascular endothelial growth factor 165 (VEGF165) could accelerate the repair of VEC injury, decrease thrombosis and thrombotic occlusion, and inhibit hyperplasia of the intima. This study was designed to construct eukaryotic expression plasmid pBudCE4.1/VEGF165, and observe its effect on the prolife ration of VEC. METHODS:The VEGF165 gene cloned from human heart tissue by RT-PCR was cloned into eukaryotic expression plasmid pBudCE4.1. The recombinant expression plasmid pBudCE4.1/VEGF165 was identified by restriction enzyme (Hind III and BamH I) digestion analysis, and was sequenced. The pBudCE4.1/VEGF165 was introduced into VEC through lipofection transfection. The VEGF165 mRNA expression by Northern blot and VEGF165 protein expression was detected by immunocytochemical staining. The effect of expression protein on VEC proliferation was detected by flow cytometry. RESULTS:The RT-PCR product of the VEGF165 gene was about 576bp. Sequencing analysis revealed that the sequence of the amplified VEGF165 gene was identical with that in GenBank. Restrictive enzyme digestion analysis showed that recombinant expression plasmid pBudCE4.1/ tVEGF165 had been constructed successfully. The expression of VEGF165 at mRNA and protein levels in the transformed VSMCs had been demonstrated by Northern blot and immunocytochemical staining respectively. The expressed product of VEGF165 could notably accelerate the proliferation of VECs. CONCLUSIONS:pBudCE4.1/VEGF165 is successfully cons- tructed and is expressed in VECs. Expressed VEGF165 can accelerate the VEC proliferation. The present study has laid a foundation for potential use of VEGF165 gene transfection to prevent and treat vascular stenosis in the transplanted organ.

Expression of Avian Reovirus (ARV) σA Protein in HEK293T Cells

[Objective]The paper was to construct eukaryotic expression vector of Avian reovirus(ARV)σA gene and expressσA protein accurately in HEK293T cells.[Method]The specific primers of ARVσA gene were designed according to the gene sequence of ARV S2 gene in GenBank(accession number KF741763.1).With pMD18-T-σA recombinant vector as the template,the specific sequence ofσA gene was amplified by PCR and cloned into pMD18-T vector to construct recombinant plasmid.The cloning vector pMD18-T-σA and eukaryotic expression plasmid pEF1α-HA were double digested by restriction enzymes Kpn I and Not I.The purifiedσA gene was connected with pEF1α-HA to construct eukaryotic expression plasmid pEF1α-HA-σA.After colony PCR,double enzyme digestion and sequencing,the recombinant plasmid pEF1α-HA-σA was tansfected into HEK293T cells.The proteins were collected at 24 h after tansfection and verified by Western-blot.[Result]The ARVσA gene was successfully cloned in the test.The eukaryotic expression plasmid pEF1α-HA-σA was constructed,which could be expressed in HEK293T cells.[Conclusion]The protein could be accurately expressed in HEK293T cells.

Construction of Three Nucleic Acid Vaccines of Swine Hepatitis E Virus ORF2 Ger\e Continuous Fragment

In order to develop swine hepatitis E （HE） genetically engineering vaccines, specific primers of genes LB1, LB2, LB3 of swine hepatitis E virus were designed and used for amplification, DNA amplieons generated by PCR assays were directly cloned into T-A plasmid and expressed using pEASY-M1 expression vector. Three recombinant eukaryotic expression plasmids of pEASY-LB1, pEASY-LB2 and pEASY-LB3 were constructed. The eukaryotic expression plasmids of pEASY-LB1, pEASY-LB2, and pEASY-LB3 were transfected into 293T cells, and three target genes were detected by real-time fluorescent quantitative RT-PCR. The results confirmed that three eukaryotic expression plasmids were transfected into 293Teells and target protein was expressed. Analysis by SDS-PAGE electrophoresis and Western-blot indicated that three target proteins were expressed in 293T cells transfected with eukaryotic expression plasmids of pEASY-LB1, pEASY-LB2 and pEASY-LB3. Antigenicity studies indicated good HEV responses. Therefore, three recombinant DNAs of HEV ORF2 nucleic acid vaccine candidates were ob- tained, which might lay the foundation for further studies in the future.

Growth inhibitory effects of THY1 gene on epithelial ovarian cancer SKOV3 cells

Objective： The aim of this study was to construct THY1 eukaryotic expression plasmid ,and study its effects on ovarian cancer SKOV3 cells. Methods： The gene fragment coding for THY1 was obtained from human normal ovarian tissue using RT-PCR, and inserted into the eukaryotic expression plasmid pcDNA3.1 （＋） to construct the recombinant plas- mid pcDNA3.1（＋）-THY1, which was transfected into SKOV3 cells. The experimental cells were classified into three groups： SKOV3-THY1, SKOV3-Null and SKOV3. The expression of gene was measured using RT-PCR and Western blotting. The percentage of apoptotic cells and cell cycle analysis and cell proliferation were assessed by flow cytometry and MTT assay. Both SKOV3-THY1 and SKOV3-null cells were inoculated subcutaneously into nude mice to determine in vivo tumorigenicity. Results： The gene fragment of THY1 was correctly inserted into the eukaryotic expression plasmid pcDNA3.1 （＋） and veri- fied by PCR, restriction endonucleases digestion and DNA sequencing and the plasmid of pcDNA3.1（＋）-THY1 （THY1 gene overexpression） has been stably transfected into SKOV3 cells. The analysis of flow cytometry indicated that the pcDNA3.1（＋）- THY1 transfected ceils in G1 phase were significantly elevated, but in S phase were decreased. The growth of transfected cells was suppressed, and more apoptosis cells were identified in pcDNA3.1（＋）-THY1 transfectants compared with vector vehicle transfectants. The tumor suppressing activity of THY1 in SKOV3 cells was associated with inhibition of SKOV3 cellular proliferation, in vivo tumorigenesis in nude mice. Conclusion： THY1 transfection can inhibit the growth of SKOV-3 cells in vitro and in vivo. THY1 gene may play an important role in generation and development of ovarian cancers.

Combinatorial effects of NaomaiYihao Capsules(脑脉一号胶囊) and vascular endothelial growth factor gene-transfected bone marrow mesenchymal stem cells on angiogenesis in cerebral ischemic tis sues in rats

OBJECTIVE:To investigate the combinatorial effects of Naomai Yihao(NMYH) Capsules(脑脉一号胶囊) and vascular endothelial growth factor(VEGF) gene-transfected bone marrow mesenchymal stem cells(BMSCs) on angiogenesis in cerebral ischemic tissues in rats and the mechanism.METHOD:BMSCs were isolated and cultured from bone marrow by an adherence method.Then,BMSCs were transfected with the eukaryotic expression plasmid pEGFP-VEGF 165 by positive ionic liposome transfection.A rat model of middle cerebral artery occlusion(MCAO) was established.Rats were allocated to six groups:model,BMSC,VEGF gene-transfected BMSC transplantation(BMSC/VEGF),NMYH,combined NMYH and BMSC/VEGF(combined treatment group) and sham operation groups.The behavioral rating score(BRS) of rat and the expression of CD34 and VEGF in brain tis sue were measured by immunohistochemistry on days 7,14 and 21 after reperfusion.Angiogenesi was observed and evaluated with laser scanning confocal microscopy.RESULTS:The BRS of rats in NMYH,BMSC transplan tation and combined treatment groups was significantly lower than that of the model group(P< 0.001),with no significant difference between NMYH and transplantation groups(P=0.619).The expression of CD34 andVEGF in NMYH,transplanta tion and combined treatment groups increased(P< 0.001),with a significant difference between NMYH and transplantation groups(P<0.001).The blood vessel area in NMYH,transplantation and com bined treatment groups was significantly increased(P<0.05),without a significant difference between NMYH and transplantation groups(P=0.873).CONCLUSIONS:VEGF gene-transfected BMSCs im prove angiogenesis in the cerebral ischemic area NMYH Capsules promote angiogenesis in MCAO rats treated with BMSC transplantation,which show an improved BRS.The mechanism of angio genesis may be related to up-regulation ofVEGF ex pression.